0.5749
2.64%
-0.0131
전일 마감가:
$0.588
열려 있는:
$0.571
하루 거래량:
98,282
Relative Volume:
0.21
시가총액:
$24.28M
수익:
$1.38M
순이익/손실:
$-179.05M
주가수익비율:
-0.0809
EPS:
-7.11
순현금흐름:
$-155.03M
1주 성능:
+10.01%
1개월 성능:
+4.24%
6개월 성능:
-71.52%
1년 성능:
-85.32%
바이오엑셀 테라퓨틱스 Stock (BTAI) Company Profile
명칭
Bioxcel Therapeutics Inc
전화
203-643-8060
주소
555 LONG WHARF DRIVE, NEW HAVEN, CT
BTAI을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
BTAI | 0.5701 | 24.28M | 1.38M | -179.05M | -155.03M | -7.11 |
VRTX | 449.11 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 746.63 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 597.08 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 246.44 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 108.09 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
바이오엑셀 테라퓨틱스 Stock (BTAI) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2023-08-15 | 다운그레이드 | Mizuho | Buy → Neutral |
2023-07-17 | 다운그레이드 | Guggenheim | Buy → Neutral |
2023-03-10 | 다운그레이드 | Jefferies | Buy → Hold |
2022-12-01 | 업그레이드 | Goldman | Sell → Neutral |
2022-07-07 | 개시 | Mizuho | Buy |
2022-04-06 | 재확인 | BofA Securities | Buy |
2021-11-15 | 다운그레이드 | Goldman | Neutral → Sell |
2021-04-09 | 개시 | Berenberg | Buy |
2021-02-01 | 개시 | UBS | Buy |
2020-10-30 | 개시 | Goldman | Buy |
2020-09-02 | 개시 | Jefferies | Buy |
2020-08-17 | 재확인 | H.C. Wainwright | Buy |
2020-07-08 | 재확인 | H.C. Wainwright | Buy |
2020-06-04 | 개시 | Guggenheim | Buy |
2020-04-01 | 개시 | BofA/Merrill | Buy |
2020-02-26 | 재확인 | H.C. Wainwright | Buy |
2020-01-08 | 재확인 | H.C. Wainwright | Buy |
2019-11-12 | 개시 | SunTrust | Buy |
모두보기
바이오엑셀 테라퓨틱스 주식(BTAI)의 최신 뉴스
BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Lags Revenue Estimates - MSN
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2024 Earnings Call Transcript - Insider Monkey
BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and Financial Adjustments - GuruFocus.com
BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and ... By GuruFocus - Investing.com Canada
BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and ... - Yahoo Finance
BioXcel Therapeutics Inc. (BTAI) Quarterly 10-Q Report - Quartz
BioXcel Therapeutics stock hits 52-week low at $0.5 By Investing.com - Investing.com Australia
BioXcel Therapeutics Reports Q3 2024 Financial Results - TipRanks
BioXcel Therapeutics stock hits 52-week low at $0.5 - Investing.com India
Earnings call: BioXcel Therapeutics reports Q3 2024 financials - Investing.com
BioXcel Therapeutics earnings beat by $0.19, revenue fell short of estimates - Investing.com Canada
BioXcel Therapeutics Inc Reports Q3 2024 Earnings: Net Revenue a - GuruFocus.com
BioXcel Therapeutics Reports Third Quarter 2024 Financial Results - GlobeNewswire
Critical Survey: Emergent BioSolutions (NYSE:EBS) vs. BioXcel Therapeutics (NASDAQ:BTAI) - Defense World
What To Expect From BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings - GuruFocus.com
BioXcel Therapeutics (BTAI) Set to Announce Earnings on Thursday - Defense World
BioXcel advances trials for acute agitation treatments - Investing.com India
BioXcel advances trials for acute agitation treatments By Investing.com - Investing.com UK
BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer's Dementia - The Manila Times
BioXcel Therapeutics Advances Pivotal Phase 3 Trials of - GlobeNewswire
BioXcel's Phase 3 Breakthrough: First Patient Enrolled in Critical Agitation Treatment Trial | BTAI Stock News - StockTitan
BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024 - GlobeNewswire
Will BioXcel Therapeutics, Inc. (BTAI) Report Negative Q3 Earnings? What You Should Know - MSN
ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSEL, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionBTAI - Marketscreener.com
BioXcel Therapeutics to Present at ThinkEquity Conference - The Manila Times
Pre-market Movers: EVOK, HCTI, GLUE, MNPR... - RTTNews
BioXcel Therapeutics (NASDAQ:BTAI) PT Lowered to $5.00 - Defense World
BioXcel announces defense grant to UNC to fund study for treating acute stress disorder - MSN
BioXcel Therapeutics partners with UNC for ASD trial By Investing.com - Investing.com Australia
BioXcel Therapeutics partners with UNC for ASD trial - Investing.com India
BioXcel Therapeutics Announces U.S. Department of Defense - GlobeNewswire
BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder - StockTitan
BioXcel Therapeutics reports executive transition - Investing.com India
BioXcel Therapeutics reports executive transition By Investing.com - Investing.com Australia
Investing in BioXcel Therapeutics Inc (BTAI) Is Getting More Attractive - Knox Daily
BioXcel Therapeutics executive sells shares worth over $3,000 By Investing.com - Investing.com Australia
BioXcel Therapeutics CSO sells shares worth $3,946 By Investing.com - Investing.com South Africa
BioXcel Therapeutics executive sells shares worth $3,449 By Investing.com - Investing.com Australia
BioXcel therapeutics officer Javier Rodriguez sells shares worth $3,774 By Investing.com - Investing.com South Africa
Bioxcel therapeutics CFO sells shares worth $3,946 By Investing.com - Investing.com Canada
Bioxcel therapeutics CFO sells shares worth $3,946 - Investing.com
BioXcel Therapeutics executive sells shares worth over $3,000 - Investing.com
BioXcel Therapeutics CSO sells shares worth $3,946 - Investing.com India
BioXcel therapeutics officer Javier Rodriguez sells shares worth $3,774 - Investing.com
BioXcel Therapeutics executive sells shares worth $3,449 - Investing.com
바이오엑셀 테라퓨틱스 (BTAI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):